1. Home
  2. PTCT vs HAE Comparison

PTCT vs HAE Comparison

Compare PTCT & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PTC Therapeutics Inc.

PTCT

PTC Therapeutics Inc.

SELL

Current Price

$63.51

Market Cap

5.5B

Sector

Health Care

ML Signal

SELL

HAE

Haemonetics Corporation

SELL

Current Price

$120.98

Market Cap

4.8B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PTCT
HAE
Founded
1998
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
4.8B
IPO Year
2006
1996

Fundamental Metrics

Financial Performance
Metric
PTCT
HAE
Price
$63.51
$120.98
Analyst Decision
Buy
Buy
Analyst Count
14
11
Target Price
$101.07
★ $122.20
AVG Volume (30 Days)
★ 1.2M
605.0K
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 264.48
N/A
EPS
★ 0.90
0.72
Revenue
$264,734,000.00
★ $910,373,000.00
Revenue This Year
N/A
$6.27
Revenue Next Year
$9.26
$5.86
P/E Ratio
★ $71.38
$165.10
Revenue Growth
★ 36.19
N/A
52 Week Low
$61.23
$48.55
52 Week High
$90.87
$121.19

Technical Indicators

Market Signals
Indicator
PTCT
HAE
Relative Strength Index (RSI) 40.49 77.14
Support Level $62.46 $72.93
Resistance Level $72.86 N/A
Average True Range (ATR) 2.00 3.12
MACD 0.19 1.24
Stochastic Oscillator 38.57 98.90

Price Performance

Historical Comparison
PTCT
HAE

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

About HAE Haemonetics Corporation

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.

Share on Social Networks: